Treats Erosive Esophagitis Associated with Gastroesophageal Reflux Disease (GERD)…. ANDA 217923, held by Aurobindo Pharma Ltd. Pantoprazole Sodium.
As of Nov 16, 2026, ANDA 217923 (Pantoprazole Sodium), held by Aurobindo Pharma Ltd, was first approved by FDA on Mar 31, 2025, with 0 approved supplements and 0 published complete response letters.
Pantoprazole sodium for delayed-release oral suspension is indicated for: Pantoprazole sodium is a proton pump inhibitor (PPI) indicated for the following: Short-Term Treatment of Erosive Esophagitis Associated with Gastroesophageal Reflux Disease (GERD) Maintenance of Healing of Erosive Esophagitis Pathological Hypersecretory Conditions Including Zollinger-Ellison (ZE) Syndrome 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 31, 2025 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Pantoprazole SodiumEQ 40MG BASE · for suspension, delayed release;oral | Pantoprazole Sodium | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters